Brokerages Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $34.40

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has earned a consensus recommendation of "Buy" from the six analysts that are presently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have covered the stock in the last year is $34.40.

ENGN has been the topic of several recent research reports. Morgan Stanley assumed coverage on shares of enGene in a research report on Friday, March 8th. They set an "overweight" rating and a $40.00 target price on the stock. SVB Leerink assumed coverage on enGene in a research report on Tuesday, February 20th. They set an "outperform" rating and a $31.00 price objective on the stock. Guggenheim assumed coverage on enGene in a report on Monday, April 15th. They issued a "buy" rating and a $34.00 target price for the company. Wells Fargo & Company assumed coverage on enGene in a report on Monday. They set an "overweight" rating and a $30.00 price target on the stock. Finally, Leerink Partnrs restated an "outperform" rating on shares of enGene in a research report on Tuesday, February 20th.

enGene Stock Down 0.3 %

enGene stock traded down $0.05 during mid-day trading on Monday, reaching $14.80. 65,845 shares of the company's stock traded hands, compared to its average volume of 43,481. enGene has a 12-month low of $6.69 and a 12-month high of $43.00. The firm's 50 day moving average price is $15.97.

Insider Activity

In related news, major shareholder De Solidarite Des Travai Fonds sold 4,575 shares of the firm's stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $15.01, for a total transaction of $68,670.75. Following the completion of the sale, the insider now directly owns 3,084,107 shares of the company's stock, valued at approximately $46,292,446.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ENGN. Vivo Capital LLC bought a new stake in enGene during the 4th quarter valued at about $6,264,000. Omega Fund Management LLC purchased a new position in shares of enGene during the fourth quarter worth approximately $10,441,000. BVF Inc. IL bought a new stake in shares of enGene during the fourth quarter valued at approximately $20,777,000. Finally, Fcpm Iii Services B.V. bought a new stake in shares of enGene during the fourth quarter valued at approximately $80,097,000. 64.16% of the stock is currently owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.